DarioHealth Corp. (NASDAQ:DRIO) Short Interest Down 11.4% in January

DarioHealth Corp. (NASDAQ:DRIO) saw a significant decline in short interest in the month of January. As of January 31st, there was short interest totalling 2,710,000 shares, a decline of 11.4% from the January 15th total of 3,060,000 shares. Based on an average trading volume of 610,800 shares, the short-interest ratio is presently 4.4 days.

Institutional Investors Weigh In On DarioHealth

Hedge funds have recently made changes to their positions in the business. Appian Way Asset Management LP raised its holdings in shares of DarioHealth by 2.5% during the third quarter. Appian Way Asset Management LP now owns 1,410,870 shares of the company’s stock valued at $1,580,000 after buying an additional 34,990 shares during the last quarter. DLK Investment Management LLC raised its holdings in shares of DarioHealth by 40.9% during the fourth quarter. DLK Investment Management LLC now owns 141,657 shares of the company’s stock valued at $111,000 after buying an additional 41,107 shares during the last quarter. Finally, XTX Topco Ltd raised its holdings in shares of DarioHealth by 81.4% during the third quarter. XTX Topco Ltd now owns 29,455 shares of the company’s stock valued at $33,000 after buying an additional 13,219 shares during the last quarter. Institutional investors own 33.39% of the company’s stock.

DarioHealth Stock Performance

DRIO stock traded up $0.02 during midday trading on Tuesday, reaching $0.72. The company had a trading volume of 2,945,332 shares, compared to its average volume of 1,215,975. The company has a quick ratio of 1.32, a current ratio of 1.57 and a debt-to-equity ratio of 0.35. The stock has a 50 day moving average price of $0.73 and a 200 day moving average price of $0.84. DarioHealth has a fifty-two week low of $0.56 and a fifty-two week high of $2.51. The firm has a market capitalization of $24.59 million, a PE ratio of -0.77 and a beta of 1.39.

Wall Street Analyst Weigh In

Separately, TD Cowen downgraded DarioHealth from a “buy” rating to a “hold” rating and decreased their target price for the company from $2.00 to $1.00 in a research note on Wednesday, January 29th.

DarioHealth Company Profile

DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.